Loading
A phase 3 trial of Ixabepilone in Breast cancer, run by Mayo Clinic, recorded as terminated on the registry.
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer is a phase 3 interventional study registered as NCT00998738 by Mayo Clinic, with 1 participants recorded, started 2009-11 and due to reach its primary completion in 2010-07. Interventions recorded: Calcium Gluconate, Magnesium Sulfate, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Ixabepilone. Conditions recorded: Neuropathy, Pain, Recurrent Breast Carcinoma, Stage IV Breast Cancer.
Linked to the drug Ixabepilone because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ixabepilone, Breast cancer (all types) and the tag pipeline.
Shares Ixabepilone and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/